Cytogen, Inc. (KOSDAQ:217330)
South Korea · Delayed Price · Currency is KRW 3,055.00
-35.00 (-1.13%)
At close: Sep 11, 2026
Cytogen Revenue
Cytogen had revenue of 6.83B KRW in the quarter ending June 30, 2026, with 8.72% growth. This brings the company's revenue in the last twelve months to 27.38B, up 31.63% year-over-year. In the year 2025, Cytogen had annual revenue of 26.05B with 138.80% growth.
Revenue (ttm)
27.38B
Revenue Growth
+31.63%
P/S Ratio
2.58
Revenue / Employee
652.01M
Employees
n/a
Market Cap
70.65B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 26.05B | 15.14B | 138.80% |
| Dec 31, 2024 | 10.91B | 7.73B | 242.63% |
| Dec 31, 2023 | 3.18B | 2.42B | 318.57% |
| Dec 31, 2022 | 760.78M | 412.93M | 118.71% |
| Dec 31, 2021 | 347.85M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GC Medical Science | 102.16B |
| Seoulin Bioscience | 83.17B |
| Dx & Vx | 26.22B |
| Protia | 17.75B |
| HLB Panagene | 14.71B |
| 3billion | 11.71B |
| GENINUS | 11.28B |
| Median Diagnostics | 7.86B |